• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A novel neutralizing antibody against diverse clades of H5N1 influenza virus and its mutants capable of airborne transmission

tetano

Editor, Senior Moderator
Antiviral Res. 2014 Mar 25. pii: S0166-3542(14)00079-5. doi: 10.1016/j.antiviral.2014.03.005. [Epub ahead of print]
A novel neutralizing antibody against diverse clades of H5N1 influenza virus and its mutants capable of airborne transmission.
Wu R1, Li X1, Leung HC2, Cao Z1, Qiu Z1, Zhou Y3, Zheng BJ2, He Y4.
Author information
Abstract

Highly pathogenic avian influenza A virus H5N1 continues to spread among poultry and has frequently broken the species barrier to humans. Recent studies have shown that a laboratory-mutated or reassortant H5N1 virus bearing hemagglutinin (HA) with as few as four or five mutations was capable of transmitting more efficiently via respiratory droplets between ferrets, posing a serious threat to public health and underscoring the priority of effective vaccines and therapeutics. In this study, we identified a novel monoclonal antibody (mAb) named HAb21, that has a broadly neutralizing activity against all tested strains of H5N1 covering clades 0, 1, 2.2, 2.3.4, and 2.3.2.1. Importantly, HAb21 efficiently neutralized diverse H5N1 variants with single or combination forms of mutations capable of airborne transmission. We demonstrated that HAb21 blocked viral entry during the receptor-binding step by targeting a previously uncharacterized epitope at the tip of the HA head. This novel epitope closely neighbors the receptor-binding site (RBS) and the interface of HA trimer and is highly conserved among divergent H5N1 strains. Our studies provide a new tool for use either for therapeutic purposes or as a basis of vaccine development.

Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:

Epitope, H5N1, Influenza A virus, Mutation, Neutralizing antibody

PMID:
24681124
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24681124
 
Back
Top Bottom